Astellas Pharma, Inc.

Astellas Pharma, Inc.

Astellas Pharma, Inc.

Date Founded



2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, JPN

Type of Company


Employees (Worldwide)



Hospitals & Patient Services
Wholesale: Consumer Non-Durables/Sundries
Medical Products & Equipment
Medical Support Services

Company Description

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company is headquartered in Tokyo, Japan.

Contact Data
Trying to get in touch with decision makers at Astellas Pharma, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Executive Director, Communications & Corporate Citizenship

General Counsel

Chief Scientific Officer

Chief Strategy Officer

President, Development

President & Head of Development

Senior Vice President & Head of Medical Affairs, Americas

Senior Executive Officer, Director of External Affairs

Senior Vice President & Oncology Therapeutic Area Head

Board of Directors

Former President, Representative Director at Astellas Pharma, Inc.

Auditor at Koki Holdings Co. Ltd.

Professor at Waseda University

Auditor at International Certificate Authority of Management System

Chief Executive Officer at Astellas Pharma US, Inc.

Former Public Prosecutor at City of Yokohama

Former Public Prosecutor at Tokyo District Public Prosecutors Office

Chief Strategy Officer at Astellas Pharma, Inc.

Corporate Adviser at Marubeni Corporation

Paths to Astellas Pharma, Inc.
Potential Connections via
Relationship Science
Astellas Pharma, Inc.
Owners & Shareholders
Details Hidden

NAM-J’s investment philosophy has core elements including: active management focusing on fundamental research; a team approach; and thorough risk/return assessment. They offer a broad range of equity strategies, including core, value, and growth. The investment approach of the core strategy combines a bottom-up, relative value approach with rigorous fundamental research on individual stocks and a top-down overlay. The investment process is designed to add value in all market conditions over a medium- to long-term horizon. For value, they use bottom-up approach without sector constraints where the quality of stock selection is paramount. The investment process is based on a combination of rigorous quantitative screening based on valuation factors with liquidity consideration and qualitative analysis on firms’ fundamentals. The growth strategy focuses on ROE level and sustainability and fundamental strength. In conducting NAM-J’s investment decisions, they utilize a broad spectrum of information, including financial publications, third-party research materials, annual reports, prospectuses, regulatory filings, company press releases, corporate rating services, inspections of corporate activities and meetings with management of various companies.

Details Hidden

SMTAM is an active manager which offers equity, fixed income, index, and multi-asset and alternative strategies. The fund managers of their respective investment departments implement investments in line with the investment plans and manage funds. The general managers of their respective investment departments check the status of investment implementations carried out by the fund managers thereof. The firm leverages the strengths, operational structure, know-how and network of their parent company to manage assets, utilizing bottom-up and top-down quantitative investment styles to make investments through their range of funds.

Details Hidden

DAM conducts in-house research and has a strong global research network. Their investment management philosophy is based on a mid-to-long-term perspective in which they try to identify hidden values which are not yet fully recognized in the market. The firm takes a balanced approach emphasizing both fundamental and quantitative analysis. DAM’s basic assumption is that the market is not fully efficient and they employ a coherent investment process through organizational support at each phase of their 'Plan', 'Do' and 'Review' policy. They pursue stable excess mid-to long-term returns through suitable risk control, which they separate from investment management to ensure that the risk control system adequately monitors their investment process. The firm’s research team analysts and portfolio managers discuss, evaluate and communicate market events and investment opinions, seeking to maximize portfolio performance. Company visits are important components of their bottom-up research process and are a primary source for their fundamental analysis.

Recent Transactions
Details Hidden

Tillotts Pharma AG, Zeria Pharmaceutical Co., Ltd. purchase Astellas Pharma Europe Ltd. /DIFICLIR Business from Astellas Pharma, Inc.

Details Hidden

Astellas Pharma, Inc. purchases Iota Biosciences, Inc.

Details Hidden

Astellas Pharma, Inc. purchases Audentes Therapeutics, Inc.

Transaction Advisors
Legal Advisor

Advised onAstellas Pharma, Inc. purchases OSI Pharmaceuticals, Inc.

Legal Advisor

Advised onAstellas Pharma, Inc. purchases Iota Biosciences, Inc.

Investment Advisor

Advised onAstellas Pharma, Inc. purchases OSI Pharmaceuticals, Inc.

Legal Advisor

Advised onAstellas Pharma, Inc. purchases GANYMED Pharmaceuticals AG from Future Capital, MIG Verwaltungs AG, ATS Beteiligungsverwaltung GmbH

Legal Advisor

Advised onAstellas Pharma, Inc. purchases Ogeda SA from Société Régionale d'Investissement de Wallonie SA, BNP Paribas Fortis Private Equity Belgium NV, Hunza Management SARL, Investsud SA, Vesalius Biocapital Partners SARL, SFPI-FPIM (Private Equity), Fund+

Legal Advisor

Advised onAstellas Pharma, Inc., Astellas Pharma US, Inc. purchase Agensys, Inc.

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner at Morrison & Foerster LLP

Legal Advisor

Partner at Skadden, Arps, Slate, Meagher & Flom LLP


Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Key Stats and Financials As of 2020
Market Capitalization
Total Enterprise Value
Earnings Per Share
Enterprise Value / Sales
Enterprise Value EBITDAOperating
TEVNet Income
Debt TEV
Three Year Compounded Annual Growth Rate Of Revenue
Net Profit
Total Equity
Total Debt
Non-Profit Donations & Grants
Details Hidden

Oncolys BioPharma, Inc. engages in the research and development of cancer treatment therapy and diagnostics which include early detection, loco-regional therapy, prognostic test, and systemic treatments. It operates through the Pharmaceutical and Diagnostics segments. The Pharmaceutical segment deals with the research, development, manufacture, and sale of pharmaceutical products. The Diagnostics segment engages in the research, development, manufacture, and sale of test agents and equipment as well as the provision of testing services. The company was founded by Yasuo Urata on March 18, 2004 and is headquartered in Tokyo, Japan.

Details Hidden

LabCentral, Inc. provides grant making services for bio-tech companies. The firm’s services include maintenance of permits for all lab operations, mandatory EHS training and compliance for all lab users, maintenance of equipment and technical support, CRO support available on-site (FTE basis), cleaning and waste removal. The company was founded by Timothy D. Rowe, Johannes Fruehauf, Peter D. Parker in September 2012 and is headquartered in Cambridge, MA.

Details Hidden

Iota Biosciences was formed with a vision to change how the world monitors and treats disease. Building on award- winning 'neural dust' technology invented at the University of California, Berkeley, they are building a platform for the future of bioelectric medicine

Details Hidden

Co-Founder at Longitude Capital Management Co. LLC

Details Hidden

Managing Partner at Amzak Capital Management LLC

Ironwood Pharmaceuticals, Inc. Pharmaceuticals | Cambridge, Massachusetts

At Ironwood, we seek to transform knowledge into medicines that make a difference for patients. Patients shape our business. They influence our drugmaking process, helping us to understand and address their unmet medical needs, whether we’re creating a new medicine or tackling the equally challenging task of delivering that medicine to people around the world. Our employees shape our success. Since our founding in 1998, each of our employees has held shares in the company. Being owners of Ironwood means we are all careful stewards of our resources: we take a data-driven approach in which we celebrate definitive answers – whether those answers support holding steady or changing course – and we challenge every program to earn its way forward. Our discovery and development processes have generated a product that’s approved in the United States and in the European Union, as well as a robust pipeline. As we continue to do drugmaking well, we hope to inspire the support of our shareholders and earn the right to do it again – building an enduring pharmaceutical company that understands and addresses people’s needs.

Gilead Sciences, Inc. Hospitals & Patient Services | Foster City, CA

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation

Pfizer, Inc. Medical Support Services | New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Astellas Pharma, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Astellas Pharma, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Astellas Pharma, Inc..